Derek Archila
Stock Analyst at Wells Fargo
(3.71)
# 734
Out of 4,944 analysts
181
Total ratings
47.01%
Success rate
7.97%
Average return
Main Sectors:
Stocks Rated by Derek Archila
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| STRO Sutro Biopharma | Maintains: Equal-Weight | $4 → $3 | $0.78 | +282.80% | 1 | Aug 12, 2025 | |
| CABA Cabaletta Bio | Maintains: Equal-Weight | $3 → $2 | $1.33 | +50.38% | 11 | Aug 8, 2025 | |
| ASND Ascendis Pharma | Maintains: Overweight | $289 → $295 | $196.02 | +50.50% | 14 | Aug 8, 2025 | |
| ZNTL Zentalis Pharmaceuticals | Maintains: Equal-Weight | $6 → $5 | $1.41 | +254.61% | 5 | Aug 7, 2025 | |
| VRDN Viridian Therapeutics | Maintains: Equal-Weight | $27 → $26 | $17.97 | +44.69% | 2 | Aug 7, 2025 | |
| ARVN Arvinas | Maintains: Overweight | $19 → $16 | $6.80 | +135.47% | 7 | Aug 7, 2025 | |
| INCY Incyte | Upgrades: Overweight | $67 → $89 | $81.61 | +9.06% | 9 | Aug 6, 2025 | |
| ARGX argenx SE | Maintains: Overweight | $741 → $756 | $637.40 | +18.61% | 12 | Jul 31, 2025 | |
| ALMS Alumis | Initiates: Overweight | $17 | $4.46 | +281.17% | 1 | Jul 25, 2025 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Overweight | $91 → $129 | $96.39 | +33.83% | 6 | Jul 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $57 → $53 | $39.87 | +32.93% | 8 | Jun 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $17 → $25 | $5.23 | +378.01% | 2 | Jun 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $26 → $29 | $23.90 | +21.34% | 12 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $18 | $11.20 | +60.71% | 4 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $25 | $10.02 | +149.50% | 5 | Apr 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $10 | $4.45 | +124.72% | 5 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $16 → $15 | $1.68 | +792.86% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $36 | $37.95 | -5.14% | 3 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $51 | $20.09 | +153.86% | 3 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $12 → $14 | $13.01 | +7.61% | 5 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $9 | $3.91 | +130.18% | 11 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $47 → $45 | $15.20 | +196.05% | 9 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $8 → $12 | $2.24 | +435.71% | 5 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $44 → $24 | $3.02 | +694.70% | 1 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $11 | $2.63 | +318.25% | 4 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $35 → $37 | $23.80 | +55.46% | 3 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $10 | $2.44 | +309.84% | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $37 → $20 | $1.79 | +1,017.32% | 7 | May 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $3.67 | +390.46% | 1 | Aug 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $3.79 | - | 1 | Jul 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $298 → $193 | $31.67 | +509.41% | 1 | Jul 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $61 → $41 | $74.05 | -44.63% | 1 | Apr 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $480 → $160 | $14.88 | +975.27% | 3 | Mar 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $180 → $60 | $9.81 | +511.62% | 3 | Mar 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | $29 | $4.31 | +572.85% | 4 | Dec 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $50 | $1.31 | +3,716.79% | 2 | Jun 22, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $51 | $19.20 | +165.63% | 1 | Nov 15, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $88 | $23.07 | +281.45% | 1 | Sep 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $24.81 | - | 1 | Sep 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $16.60 | - | 2 | Aug 3, 2017 |
Sutro Biopharma
Aug 12, 2025
Maintains: Equal-Weight
Price Target: $4 → $3
Current: $0.78
Upside: +282.80%
Cabaletta Bio
Aug 8, 2025
Maintains: Equal-Weight
Price Target: $3 → $2
Current: $1.33
Upside: +50.38%
Ascendis Pharma
Aug 8, 2025
Maintains: Overweight
Price Target: $289 → $295
Current: $196.02
Upside: +50.50%
Zentalis Pharmaceuticals
Aug 7, 2025
Maintains: Equal-Weight
Price Target: $6 → $5
Current: $1.41
Upside: +254.61%
Viridian Therapeutics
Aug 7, 2025
Maintains: Equal-Weight
Price Target: $27 → $26
Current: $17.97
Upside: +44.69%
Arvinas
Aug 7, 2025
Maintains: Overweight
Price Target: $19 → $16
Current: $6.80
Upside: +135.47%
Incyte
Aug 6, 2025
Upgrades: Overweight
Price Target: $67 → $89
Current: $81.61
Upside: +9.06%
argenx SE
Jul 31, 2025
Maintains: Overweight
Price Target: $741 → $756
Current: $637.40
Upside: +18.61%
Alumis
Jul 25, 2025
Initiates: Overweight
Price Target: $17
Current: $4.46
Upside: +281.17%
Rhythm Pharmaceuticals
Jul 10, 2025
Maintains: Overweight
Price Target: $91 → $129
Current: $96.39
Upside: +33.83%
Jun 26, 2025
Maintains: Overweight
Price Target: $57 → $53
Current: $39.87
Upside: +32.93%
Jun 20, 2025
Maintains: Overweight
Price Target: $17 → $25
Current: $5.23
Upside: +378.01%
Jun 2, 2025
Maintains: Equal-Weight
Price Target: $26 → $29
Current: $23.90
Upside: +21.34%
May 16, 2025
Maintains: Equal-Weight
Price Target: $11 → $18
Current: $11.20
Upside: +60.71%
Apr 9, 2025
Maintains: Overweight
Price Target: $32 → $25
Current: $10.02
Upside: +149.50%
Mar 21, 2025
Maintains: Equal-Weight
Price Target: $11 → $10
Current: $4.45
Upside: +124.72%
Mar 12, 2025
Maintains: Equal-Weight
Price Target: $16 → $15
Current: $1.68
Upside: +792.86%
Feb 24, 2025
Downgrades: Equal-Weight
Price Target: $36
Current: $37.95
Upside: -5.14%
Feb 13, 2025
Maintains: Overweight
Price Target: $40 → $51
Current: $20.09
Upside: +153.86%
Dec 19, 2024
Maintains: Equal-Weight
Price Target: $12 → $14
Current: $13.01
Upside: +7.61%
Dec 19, 2024
Maintains: Equal-Weight
Price Target: $11 → $9
Current: $3.91
Upside: +130.18%
Dec 19, 2024
Maintains: Overweight
Price Target: $47 → $45
Current: $15.20
Upside: +196.05%
Dec 19, 2024
Upgrades: Overweight
Price Target: $8 → $12
Current: $2.24
Upside: +435.71%
Nov 15, 2024
Maintains: Overweight
Price Target: $44 → $24
Current: $3.02
Upside: +694.70%
Aug 12, 2024
Maintains: Overweight
Price Target: $16 → $11
Current: $2.63
Upside: +318.25%
Aug 12, 2024
Maintains: Equal-Weight
Price Target: $35 → $37
Current: $23.80
Upside: +55.46%
May 15, 2024
Maintains: Overweight
Price Target: $12 → $10
Current: $2.44
Upside: +309.84%
May 5, 2021
Downgrades: Hold
Price Target: $37 → $20
Current: $1.79
Upside: +1,017.32%
Aug 4, 2020
Initiates: Buy
Price Target: $18
Current: $3.67
Upside: +390.46%
Jul 23, 2020
Upgrades: Buy
Price Target: n/a
Current: $3.79
Upside: -
Jul 10, 2020
Downgrades: Hold
Price Target: $298 → $193
Current: $31.67
Upside: +509.41%
Apr 15, 2020
Reiterates: Buy
Price Target: $61 → $41
Current: $74.05
Upside: -44.63%
Mar 31, 2020
Maintains: Hold
Price Target: $480 → $160
Current: $14.88
Upside: +975.27%
Mar 17, 2020
Downgrades: Hold
Price Target: $180 → $60
Current: $9.81
Upside: +511.62%
Dec 11, 2018
Downgrades: Perform
Price Target: $29
Current: $4.31
Upside: +572.85%
Jun 22, 2018
Maintains: Outperform
Price Target: $34 → $50
Current: $1.31
Upside: +3,716.79%
Nov 15, 2017
Maintains: Outperform
Price Target: $32 → $51
Current: $19.20
Upside: +165.63%
Sep 7, 2017
Initiates: Outperform
Price Target: $88
Current: $23.07
Upside: +281.45%
Sep 7, 2017
Initiates: Market Perform
Price Target: n/a
Current: $24.81
Upside: -
Aug 3, 2017
Downgrades: Perform
Price Target: n/a
Current: $16.60
Upside: -